Pharmafile

MARCH 30, 2023

After receiving FDA approval in January 2023, Biogen/Eisai’s new Alzheimer’s disease Leqembi is expected to become a blockbuster, with a predicted $12.9bn predicted to be made in sales between 2023 and 2028. The drug is still awaiting approval in the EU and Japan, with these approvals potentially making it the top-selling Alzheimer’s drug.

83

83

pharmaphorum

JUNE 8, 2023

Standalone Sandoz eyes $3bn in new product sales by 2028 Phil.Taylor Thu, 08/06/2023 - 07:57 Bookmark this

90

90

Pharmaceutical Technology

MARCH 30, 2023

The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is forecast to generate total sales of $12.9bn worldwide between 2023 and 2028. The forecast total sales of $12.9bn by 2028 underscores the significant impact Leqembi is expected to have on the market.

Compounding 59

Compounding 59

STAT

NOVEMBER 14, 2024

“At Merck, we continue to assemble a strong and diversified oncology pipeline spanning differentiated mechanisms and multiple modalities,” said Dean Li, the president of Merck Research Laboratories, in a statement.

Research Laboratories 269

Research Laboratories Drug Development 269

Pharmaceutical Technology

MARCH 30, 2023

The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is forecast to generate total sales of $12.9bn worldwide between 2023 and 2028. The forecast total sales of $12.9bn by 2028 underscores the significant impact Leqembi is expected to have on the market.

Compounding 52

Compounding 52

STAT

OCTOBER 29, 2024

Beginning in 2028, Dana-Farber will end its long and nationally acclaimed adult oncology partnership with Brigham and Women’s Hospital. Instead, it will team up with Beth Israel Deaconess Medical Center to  open a new freestanding  300-bed, $1.68 billion cancer hospital in the Longwood Medical Area.

Hospitals 195

Hospitals 195

STAT

AUGUST 13, 2024

In a press release, the company said that the cuts would help it extend its cash reserves from the second half of 2026 into 2028. The Bay Area biotech brought in $32 million during the quarter but also reported a net loss of $1.6 Continue to STAT+ to read the full story…

347

347

STAT

SEPTEMBER 12, 2024

The company also said that it plans to break even by 2028, when it expects it will reach annual sales of $6 billion. The announcement was made ahead of a meeting being held by Moderna on Thursday to update investors on its research and development efforts. Continue to STAT+ to read the full story…

Drug Development 296

Drug Development Vaccines 296

STAT

MARCH 25, 2024

With the lease on its two-building campus on Fan Pier set to expire in 2028, the company is reevaluating its real estate options — and considering leaving its prominent headquarters for another spot in the neighborhood. Now, Vertex may be on the move again. Continue to STAT+ to read the full story…

Drug Development 250

Drug Development 250

Pharmaceutical Technology

OCTOBER 25, 2024

A new vaccines drug substance facility and R&D pilot plant, completed by the end of 2028, will create over 200 new jobs.

Vaccines 98

Vaccines 98

BioPharma Dive

AUGUST 29, 2024

The trial setbacks for Merck’s best-selling drug, which faces patent expiration in 2028, are a blow to the company’s plans for further indication expansion.

107

107

STAT

JUNE 3, 2024

Kaiser, which is both a health insurance company and a network of providers, said it wants to add at least five to six more health systems by 2028. Geisinger’s 10 hospitals and 1,700 employed physicians are now officially part of the group, known as Risant Health. Those other organizations are still a mystery.

Hospitals 294

Hospitals Health Insurance Companies 294

STAT

MAY 14, 2024

Last December, the agency determined the confirmatory trial was not acceptable and asked the company to run yet another trial, which must be completed by February 2028.

Dosage 326

Dosage 326

STAT

JANUARY 8, 2024

That could come as soon as 2028. The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug.

Immunization 273

Immunization Immunity 273

STAT

NOVEMBER 19, 2024

patent expires in 2028. For Merck, the new under-the-skin, or subcutaneous, formulation could represent a major way of holding on to a larger share of Keytruda’s $25 billion in annual sales than would otherwise occur when a U.S.

Biosimilars 186

Biosimilars Immunization Immunity Pharmaceutical Companies 186

STAT

SEPTEMBER 28, 2023

The split will take a few years to play out — Dana-Farber and Brigham and Women’s have a contract into 2028 — but has shaken patients and physicians. Anne Klibanski, chief executive of Brigham and Women’s parent organization, Mass General Brigham, placed the blame on Dana-Farber executives.

Hospitals 325

Hospitals 325

PharmaTech

OCTOBER 11, 2024

The draft joint network strategy for the EU until 2028 will be open for public consultation until Nov. 30, 2024.

52

52

Pharmacy Times

JANUARY 22, 2024

The IQVIA Global Use of Medicines report for 2024 predicts that loss of brand exclusivity will negatively impact global market growth.

58

58

European Pharmaceutical Review

MARCH 20, 2024

million by 2028. percent between 2022-2028, the research found. Based on the research, the US LIMS market is predicted to value $1 billion by 2028. According to a report by Arizton, the Europe laboratory information management system (LIMS) market is expected to reach $912.47 The market is growing at a CAGR of 10.16

98

98

PharmExec

JULY 18, 2023

Pharma giant to serve as Team USA’s partner in prescription medicine and health equity.

52

52

BioPharma Dive

JANUARY 29, 2024

An under-the-skin Opdivo shot produced similar results to an intravenous formulation in kidney cancer, giving Bristol Myers a chance at sustaining sales past a key patent expiration in 2028.

70

70

BioPharma Dive

APRIL 20, 2023

With the court victory, the biotech giant could stave off a set of generic competitors for the top-selling drug until 2028.

102

102

Pharmaceutical Commerce

JANUARY 18, 2024

The predicted value is largely driven by manufacturers' prioritization of brand protection.

52

52

Pharmaceutical Commerce

SEPTEMBER 25, 2023

This would signify an 8.3% CAGR over the next five years.

52

52

STAT

JULY 29, 2024

Thomas Schinecker, chief executive of the pharmaceutical company, said its first obesity drugs would come to market “significantly faster than people are expecting,” potentially by 2028. The treatments, acquired in a $3.1 reduction in weight compared with a placebo after four weeks.

Pharmaceutical Companies 234

Pharmaceutical Companies Pharmaceutical Companies 234

STAT

NOVEMBER 14, 2024

The cancer immunotherapy Keytruda, which is Merck’s most important product and the best-selling drug in the world with $23 billion in annual sales, is set to lose patent protection and face competition from generic drugmakers as early as 2028.

213

213

European Pharmaceutical Review

DECEMBER 4, 2023

billion by 2028, growing at a CAGR of 6.8 percent between 2023 to 2028. Moreover, the non-toxic nature of organic chemicals is expected to drive the organic chemicals sectors, ultimately boosting the pharmaceutical excipient market in the forecast period (2023 to 2028).

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

Pharmaceutical Technology

JANUARY 15, 2024

MSD’s blockbuster immunotherapy, set to lose patent protection in 2028, secures third FDA approval in cervical cancer.

59

59

Pharmaceutical Technology

JANUARY 9, 2024

Set to lose Keytuda patent protection in 2028, MSD is shoring up its oncology portfolio with immunotherapies.

52

52

STAT

JANUARY 25, 2023

The data is a setback for Merck, which has been working to expand use of Keytruda, which has powered its growth for years but will lose exclusivity in 2028. The drug was being tested in combination with androgen deprivation therapy and Xtandi in patients with hormone-sensitive prostate cancer that has spread to other parts of the body.

215

215

STAT

SEPTEMBER 12, 2024

In a press release issued ahead of an investor meeting today, the company also said it plans to break even by 2028, when it expects it will reach annual sales of $6 billion. … Moderna plans to cut its annual spending on research and development by 23%, or $1.1

Packaging 139

Packaging Diabetes Vaccines 139

The Pharmacist

JUNE 30, 2023

Training places for pharmacists will be expanded by almost a third (29%) by 2028/29, NHS England has announced today within its new workforce plan. And the ambition is to increase training places for the profession by nearly 50% – to around 5,000 places per year – by 2031/32, it said.

71

71

Pharmaceutical Technology

JANUARY 30, 2023

These are forecast to generate $264 billion in sales between 2021 and 2028. The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028.

Vaccines 52

Vaccines 52

Express Pharma

JANUARY 31, 2024

GlobalData’s Respiratory Syncytial Virus (RSV) Forecast in Asia-Pacific Markets to 2028 reveals that Urban China will lead the Asia-Pacific (five growth markets*) market for RSV in 2028, accounting for 34.8 Hence, the approval addresses an urgent need for novel prophylactic treatment options for the pediatric population in China.”

86

86

Pharmacy Times

AUGUST 18, 2022

Study results show a compound annual growth rate of 5.2% billion in revenue in 2021.

Compounding 26

Compounding 26

Express Pharma

NOVEMBER 13, 2024

million by 2031, assuming the asset attains approval in 2028. According to GlobalData, dapirolizumab pegol sales are expected to reach $63.4

Labelling 93

Labelling Immunity Immunization 93

European Pharmaceutical Review

JUNE 5, 2024

billion in 2028. A report by the Business Research Company predicts that the small molecule injectable drugs market will value $355.14 As such, the compound annual growth rate (CAGR) is expected to be 12.8 percent up to this period.

Compounding 97

Compounding Diabetes 97